Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
Top Page
Inmune Bio
(NASDAQ:INMB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-34.64% Downside)
Action:ReiteratedDate:03/31/26
INMB scores low primarily due to weak financial performance (multi-year cash burn and operating losses with low cash-earnings quality) and a bearish technical setup (price below key moving averages with negative MACD). The earnings call adds support via credible regulatory/clinical progress, but near-term financing needs and execution risk keep the overall score constrained.
Positive Factors
CORDStrom clinical efficacy & regulatory path
Robust randomized RDEB data plus a targeted U.K. MAA filing create a durable path to a potential first systemic therapy in an ultra‑rare disease. Orphan and rare pediatric designations and possible priority review vouchers materially improve long‑term commercial and partnership opportunity.
Negative Factors
Limited cash runway
Modest cash and a runway into Q1 2027 force near‑term fundraising or partnerships to complete registrational paths. Continued negative operating and free cash flow means recurring capital raises are likely, creating dilution risk and potential delays to late‑stage programs.
Read all positive and negative factors
Positive Factors
Negative Factors
CORDStrom clinical efficacy & regulatory path
Robust randomized RDEB data plus a targeted U.K. MAA filing create a durable path to a potential first systemic therapy in an ultra‑rare disease. Orphan and rare pediatric designations and possible priority review vouchers materially improve long‑term commercial and partnership opportunity.
Read all positive factors
Inmune Bio (INMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.09M
Dividend YieldN/A
Average Volume (3M)459.75K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth19.05%
EPS Growth2.01%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding26,585,258
10 Day Avg. Volume306,670
30 Day Avg. Volume459,751
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue238.14
Enterprise Value/Gross Profit-350.21
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Inmune Bio Business Overview & Revenue Model
Company Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, s...
How the Company Makes Money
null...
Inmune Bio Earnings Call Summary
Earnings Call Date:Mar 30, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Neutral
The call presented balanced, tangible progress on high-value clinical and regulatory fronts — notably CORDStrom's convincing RDEB data, manufacturing/CMC readiness, and INKmune Phase II success — and meaningful regulatory alignment for XPro's next-stage plan. However, these positives are tempered by a missed top-line primary endpoint for MINDFuL (leading to a $16.5M impairment), an increased net loss, a modest cash balance (~$24.8M) with runway only through Q1 2027, and the need for additional capital/partnerships and incremental CMC work for U.S. filings. Overall, the company has promising technical and regulatory momentum but faces near-term financial and execution risks that keep the picture balanced.Positive Updates
CORDStrom: Positive Clinical Efficacy and Safety in RDEB
Randomized placebo-controlled data showed clinically meaningful wound healing, reductions in itch, improvements in quality of life and a favorable safety profile for CORDStrom in RDEB; company expects to file a U.K. MAA by mid-summer 2026 and to submit EMA and U.S. (BLA) applications by end of 2026 with potential supply to patients in 2027.
Negative Updates
MINDFuL Phase II: Missed Top-Line Primary Endpoint and Impairment
Company reported the Phase II Alzheimer's trial did not meet its clinical primary endpoint; as a result INmune recognized a full impairment of an intangible asset of $16.5M in 2025.
Read all updates
Q4-2025 Updates
Positive
Negative
CORDStrom: Positive Clinical Efficacy and Safety in RDEB
Randomized placebo-controlled data showed clinically meaningful wound healing, reductions in itch, improvements in quality of life and a favorable safety profile for CORDStrom in RDEB; company expects to file a U.K. MAA by mid-summer 2026 and to submit EMA and U.S. (BLA) applications by end of 2026 with potential supply to patients in 2027.
Read all positive updates
Company Guidance
Management provided specific timing, clinical and financial guidance: they expect to file a U.K. MAA for CORDStrom by mid‑summer 2026, submit to the EMA a few months later and a BLA to the FDA toward the end of 2026 (with feedback or potential approvals in 2027 and patient supply targeted in 2027); CORDStrom is manufactured from pools of 4+ donor MSC banks (four different master seedstocks shown consistent), potency assays and an MOA have been established, and orphan + rare pediatric designations could yield a priority review voucher. For XPro the FDA has aligned on an adaptive Phase III (two‑stage with a Phase IIb decision at 9 months and a seamless registrational stage to 18 months using CDR‑Sum of Boxes as the primary endpoint). Other program and operational metrics: INKmune’s Phase II in mCRPC finished ahead of schedule and under budget, meeting its primary and 2 of 3 secondary endpoints; 2025 net loss was ~$45.9M vs $42.1M in 2024, R&D expense ~$20.7M (vs $33.2M), G&A ~$10.3M (vs $9.5M), a $16.5M intangible impairment was recorded, cash and cash equivalents were ~$24.8M at 12/31/2025, the company sold 3.0M shares for net ~$17.4M and ~1.3M shares for net ~$10.1M, had ~26.6M shares outstanding as of 3/30/2026, and believes current cash funds operations through Q1 2027.Inmune Bio Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| Gross Profit | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K |
| EBITDA | -30.79M | -42.08M | 0.00 | 0.00 | 0.00 |
| Net Income | -45.93M | -42.08M | -30.01M | -27.30M | -30.34M |
Balance Sheet | |||||
| Total Assets | 32.35M | 39.56M | 57.00M | 81.80M | 99.94M |
| Cash, Cash Equivalents and Short-Term Investments | 24.75M | 20.92M | 35.85M | 52.15M | 74.81M |
| Total Debt | 1.03M | 384.00K | 10.44M | 15.31M | 15.23M |
| Total Liabilities | 8.83M | 7.46M | 18.86M | 21.69M | 19.72M |
| Stockholders Equity | 23.52M | 32.10M | 38.14M | 60.10M | 80.22M |
Cash Flow | |||||
| Free Cash Flow | -23.62M | -33.36M | -11.98M | -22.69M | -43.50M |
| Operating Cash Flow | -22.58M | -33.36M | -11.98M | -22.69M | -28.50M |
| Investing Cash Flow | -1.04M | 0.00 | 0.00 | 0.00 | -15.00M |
| Financing Cash Flow | 27.61M | 18.21M | -4.22M | 729.00K | 96.36M |
Inmune Bio Technical Analysis
Neutral
1.53
Price Trends
1.32
Positive
1.51
Negative
1.81
Negative
Market Momentum
-0.01
Negative
54.60
Neutral
74.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Neutral. The current price of 1.53 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.32, and below the 200-day MA of 1.81, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.60 is Neutral, neither overbought nor oversold. The STOCH value of 74.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INMB.
Inmune Bio Risk Analysis
Inmune Bio disclosed 59 risk factors in its most recent earnings report. Inmune Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inmune Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $70.74M | 5.20 | -165.19% | ― | -25.51% | 49.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $192.97M | -0.41 | 77.87% | ― | -3.98% | -29.94% | |
46 Neutral | $35.09M | -0.90 | -171.01% | ― | 19.05% | 2.01% | |
46 Neutral | $39.00M | ― | -83.24% | ― | -100.00% | 55.10% | |
44 Neutral | $36.05M | -0.59 | 763.31% | ― | -15.81% | -113.06% |
* Healthcare Sector Average
INMB
Inmune Bio
1.32
-6.00
-81.97%
VERU
Veru
2.43
-2.91
-54.49%
KPTI
Karyopharm Therapeutics
8.56
3.61
72.93%
CUE
Cue Biopharma
0.72
-0.04
-4.99%
CELU
Celularity
1.25
-0.31
-19.87%
JUNS
Jupiter Neurosciences, Inc.
0.40
-0.22
-35.81%
Inmune Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
Positive
Feb 27, 2026
INmune Bio has released a new corporate slide presentation dated March 2025 outlining its late-stage pipeline in inflammation and immunology, with an emphasis on CORDStrom as a systemic therapy for the ultra-rare skin disorder RDEB and XPro1595 fo...
Business Operations and StrategyProduct-Related Announcements
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
Positive
Feb 23, 2026
INmune Bio Inc., a clinical-stage biotechnology company specializing in inflammation and immunology, is advancing a pipeline that includes CORDStrom™ for rare dermatologic disease, XPro™ as a selective soluble TNF inhibitor targeting n...
Business Operations and StrategyProduct-Related Announcements
INmune Bio to Present New CORDStrom Phase III Data
Positive
Feb 19, 2026
On February 19, 2026, INmune Bio announced plans to host a webinar on February 26, 2026, to present new clinical data on its CORDStrom cell therapy candidate for recessive dystrophic epidermolysis bullosa. The MissionEB Phase III trial data to be ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
Positive
Feb 13, 2026
On February 10, 2026, INmune Bio submitted a pre-submission package to the U.K. Medicines and Healthcare Products Regulatory Agency for CORDStrom, a potential first systemic therapy for recessive dystrophic epidermolysis bullosa, following encoura...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
INmune Bio outlines 2026 regulatory path in shareholder letter
Positive
Jan 27, 2026
In a shareholder letter dated January 27, 2026, INmune Bio reviewed 2025 as a pivotal year marked by progress in two lead programs and solidified financial footing. The company reported substantial advances in CORDStrom™ for RDEB, including ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.